Back to top
more

Bristol Myers Squibb (BMY)

(Real Time Quote from BATS)

$44.06 USD

44.06
6,742,754

-0.05 (-0.11%)

Updated May 17, 2024 02:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Exelixis (EXEL) Stock Gains 41.8% So Far in 2023: Here's Why

by Zacks Equity Research

Exelixis' (EXEL) lead drug Cabometyx maintains momentum on consistent demand. Its efforts to develop additional drugs to expand its portfolio are poised to reap rewards for the company.

Why Is Repligen (RGEN) Up 2.9% Since Last Earnings Report?

by Zacks Equity Research

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $61.65, marking a -1.17% move from the previous day.

Vertex (VRTX) Down 2.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More

by Zacks Equity Research

Regulatory updates from Fibrogen (FGEN) and Bristol Myers (BMY) are in focus in the biotech sector.

Medicare's First Price Negotiation List Targets Expensive Drugs (Revised)

by Zacks Equity Research

The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $62.38, marking a -0.75% move from the previous day.

Apellis Pharmaceuticals, Inc. (APLS) Up 67.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kinjel Shah headshot

Medicare's First Price Negotiation List Targets Expensive Drugs

by Kinjel Shah

The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.

10 Drugs Selected for Medicare Price Reduction

by Zacks Equity Research

10 Drugs Selected for Medicare Price Reduction

Mark Vickery headshot

Medicare Drugs Targeted Under Inflation Reduction Act

by Mark Vickery

Last year, these 10 drugs made up $50 billion, about 20%, of Medicare part D costs.

Bristol Myers (BMY) Gets FDA Nod for Reblozyl Label Expansion

by Zacks Equity Research

Bristol Myers' (BMY) Reblozyl is now indicated in the United States as the first-line treatment of anemia in adults with lower-risk MDS who may require transfusions.

Exelixis (EXEL) Late-Stage Study in Pancreatic Tumors Positive

by Zacks Equity Research

Exelixis' (EXEL) phase III CABINET study shows dramatic improvement in efficacy in advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine tumors.

Bristol Myers' (BMY) Opdivo Gets EC Nod for Label Expansion

by Zacks Equity Research

Bristol Myers (BMY) obtains approval in the EU for Opdivo for the adjuvant treatment of adults and adolescents with stage IIB or IIC melanoma who have undergone complete resection.

Exelixis' (EXEL) Prostate Cancer Study Meets Primary Endpoint

by Zacks Equity Research

Exelixis (EXEL) and partner Ipsen's phase III CONTACT-02 study meets one of the two primary endpoints in prostate cancer patients.

Bristol Myers (BMY) Announces Positive Updated NSCLC Data

by Zacks Equity Research

Bristol Myers' (BMY) repotrectinib shows durable efficacy benefits in patients with locally advanced or metastatic ROS1-Positive non-small cell lung cancer.

Pfizer (PFE) Seems Well-Poised for Long-Term Growth: Here's How

by Zacks Equity Research

Though Pfizer's (PFE) revenues from COVID products are declining sharply, it is set to launch some key non-COVID products in 2023, which can drive long-term sales and profit growth.

Sheraz Mian headshot

Top Analyst Reports for Oracle, Chevron & Linde

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Oracle Corporation (ORCL), Chevron Corporation (CVX) and Linde plc (LIN).

Sweta Killa headshot

Pharma ETFs in Focus Post Q2 Earnings

by Sweta Killa

Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.

Mirati (MRTX) Q2 Earnings Beat, Stock Up on Solid Krazati Sales

by Zacks Equity Research

Mirati (MRTX) reports better-than-expected second-quarter earnings while revenues miss by a slight margin. Its CEO steps down. The stock climbs 9%.

Prothena (PRTA) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Prothena (PRTA) reports a wider-than-expected loss in the second quarter. The company makes considerable pipeline progress and updates 2023 bottom-line guidance.

Editas' (EDIT) Q2 Earnings Beat, Sales Miss, Pipeline in Focus

by Zacks Equity Research

Editas (EDIT) reports mixed second-quarter 2023 results. EDIT-301 studies remain on track to provide updates by the end of the year. The stock of the company rises about 6% on Wednesday.

Shaun Pruitt headshot

Here's Why Investors Should Buy These 2 Medical Stocks After Earnings

by Shaun Pruitt

Following their favorable Q2 reports now looks like a good time to buy Encompass Health (EHC) and Vertex Pharmaceuticals (VRTX) stock.

Exelixis (EXEL) Q2 Earnings Top, Cabometyx Drives Growth

by Zacks Equity Research

Exelixis (EXEL) beats second-quarter 2023 earnings and sales estimates as Cabometyx drives growth in approved indications.

Pfizer's (PFE) Q2 Earnings Beat, Sales Miss, Stock Declines

by Zacks Equity Research

Pfizer (PFE) beats estimates for second-quarter earnings but misses the same for sales. It trims the upper end of its revenue guidance range for 2023. Stock falls.